To revolutionise the treatment of cerebrovascular and neurodegenerative diseases where there is no effective drug therapy available today.
Diseases of cerebrovascular origins such as resistant hypertension, stroke, Alzheimer’s disease and vascular dementia rank alongside cancer as one of the greatest healthcare challenges faced by humanity, affecting one in three in later life.
Currently, there are no efficient drugs or treatment proven to modify the course of these diseases. Bioinduction has developed a precisely targetted brain pacemaker that offers new hope for the millions of sufferers.
As Wired Health reports: “the future of medication isn’t drugs and their countless side effects but electrical implants!”
1
billion
people across the
world have hypertension
140
million
are not managed
by drugs
7.5
million
die annually worldwide from heart disease and stroke caused by high blood pressure
The Solution
New brain targets identified
Cerebrovascular diseases have one thing in common: a reduction in the cerebral blood flow.
Bioinduction has developed and patented a new treatment that restores normal blood flow to the brain.
Skull-mounted brain pacemaker
To give millions of people access to this treatment, we have developed Picostim, a miniaturised brain pacemaker, which is small enough to be skull-mounted.
Picostim is a third of the size of current devices and can be implanted in half the time.
potential to improve lives of millions of people
Team
We have a strong and experienced team to deliver our mission. We all have experience in medical device design and clinical investigations and are continually building our expert team to accelerate our product development and continue to develop the clinical evidence.
Nik Patel
Co-Founder
Senior Functional Neurosurgeon.
Inventor of new treatments for cerebrovascular conditions.
Ivor Gillbe
Co-Founder
Inventor of key device technology.
Two previous technology exits.
Anton Jenkins
Non-exec
Investor and strategic advisor.
Co-founder of Clinigen Group Plc.
Khalid Ishaque
Former CEO Pixium Vision, GM Neuromodulation international Boston Scientific
Jon Ottaway
Technical architect of Picostim system
15 years’ experience in medical devices software and hardware development.
Barry Taylor
Quality and regulatory manager
29 years in implantable medical devices
Chartered quality professional
Work with us
Get in touch today to discuss our current career opportunities:
News
- 31 JAN 2023: Bioelectronic implant offers an intelligent therapy to treat incontinence (ox.ac.uk)
- 31 JAN 2023: Oxford spinout trials revolutionary bioelectronic implant to treat incontinence (ox.ac.uk)
- 26 APR 2022: Parkinson’s disease symptoms ‘reversed’ by mini implant, trial suggests (bbc.com)
- 26 APR 2022: World’s smallest Deep Brain Stimulation (DBS) device on trial at North Bristol NHS Trust (nbt.nhs.uk) + Patient Video
- 31 MAR 2022: Oxford Team Locates New DBS Target for Brain Disorder (neurotechreports.com)
- 03 MAR 2022: SEEKING: Quality Assurance and Regulatory Affairs Manager (more details here)
- 07 FEB 2022: First-in-human implant of a “closed-loop” bioelectronic research system for investigating treatments for brain disorders (eng.ox.ac.uk)
- 30 JUN 2021: Bioinduction Announces the World’s First Successful Implantations of ‘PICOSTIM’, a Novel, Less Invasive, Self-Contained Cranialized ‘Brain Pacemaker’ for Parkinson’s Disease (prnewswire.com)